Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 4, 2017

View Archived Issues

Medsenic's arsenic trioxide awarded E.U. orphan drug designation for GvHD, begins phase II trial

Novel prototypical peptidomimetic inhibitor demonstrates efficacy in models of AML

IMPDH inhibition as a promising new therapeutic strategy against MLL-fusion leukemia

AMPK identified as a novel therapeutic target in acute lymphoblastic leukemia

Researchers identify a novel target for AML and MDS

Xenikos obtains funding to support T-Guard development

Flamel Technologies now Avadel Pharmaceuticals

Axsome Therapeutics cleared to begin phase II/III study of AXS-05 in Alzheimer's

Bayer Pharma patents muscarinic acetylcholine M2 receptor PAMs

University of Florida discloses aminoacyl-tRNA synthetase inhibitors

Zynerba Pharmaceuticals commences FAB-C study of ZYN-002 gel

Abeona Therapeutics' ABO-201 granted orphan drug designation in Europe

Inventiva initiates patient enrollment in phase IIb study of IVA-337

Almirall describes JAK inhibitors

Soliqua available in U.S.

Adhaere Pharmaceuticals presents anticancer agents

Kite Pharma submits IND for phase I study of KITE-718

GSK closes agreement to divest non-core assets to Aspen

FDA grants priority review to Stivarga sNDA for hepatocellular carcinoma

Astellas Pharma discloses dopamine D1 receptor PAMs

Seattle Genetics presents new clinical data for vadastuximab talirine

Agile reports phase III topline results for Twirla hormonal contraceptive patch

Newron Pharmaceuticals reports promising results for evenamide in schizophrenia

Inspyr Therapeutics to study mipsagargin combination therapies

NewVac's phase II study of quisinostat meets primary endpoints

Inotek reports topline results from pivotal trial of trabodenoson for glaucoma

Acura explores financing and strategic alternatives

CymaBay Therapeutics signs license agreement with Kowa for arhalofenate in U.S.

Cellectis submits IND to begin phase I trials of UCART-123

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 4, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...